An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.